2Decisions
2Patient groups

Added benefit by patient group

  • Deemed proven2

Decisions, newest first

Each decision lists only the patient groups coded with this disease.

Xydalba

Decision dated 2025-11-20
Deemed proven
Kinder ab Geburt bis

Active substance

Dalbavancin

Appropriate comparator therapy

N/A

ICD codes

  • L03.11
  • L03.10
  • L03.01
  • L03.02
  • L03.9
  • L03.2
  • L03.3
  • L03.8
Diagnoses
  • Fußphlegmone
  • Armphlegmone
  • Fingerphlegmone
  • Zehenphlegmone
  • Cellulitis
  • Gesichtsphlegmone
  • Rumpfphlegmone
  • Kopfphlegmone a.n.k.

Xydalba

Decision dated 2024-02-01
Deemed proven
Erwachsene und Kinder ab 3 Monaten mit einer akuten bakteriellen Haut- und Weichgewebeinfektionen (ABSSSI)

Active substance

Dalbavancin

Appropriate comparator therapy

N/A

ICD codes

  • L03.01
  • L03.11
  • L03.02
  • L03.2
  • L03.9
  • L03.10
  • L03.3
  • L03.8
Diagnoses
  • Fingerphlegmone
  • Fußphlegmone
  • Zehenphlegmone
  • Gesichtsphlegmone
  • Cellulitis
  • Armphlegmone
  • Rumpfphlegmone
  • Kopfphlegmone a.n.k.

Disease names are the official German titles of ICD-10-GM, version 2026.

Die Erstellung erfolgt unter Verwendung der maschinenlesbaren Fassung des Bundesinstituts für Arzneimittel und Medizinprodukte (BfArM).

In English: created using the machine-readable version of the Federal Institute for Drugs and Medical Devices (BfArM).

Data status: 2026-10-29